Phio Pharmaceuticals Stock (NASDAQ:PHIO)


RevenueOwnershipFinancialsChart

Previous Close

$3.08

52W Range

$2.40 - $29.07

50D Avg

$3.07

200D Avg

$5.65

Market Cap

$2.49M

Avg Vol (3M)

$49.28K

Beta

1.45

Div Yield

-

PHIO Company Profile


Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

May 10, 2012

Website

PHIO Performance


PHIO Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-10.82M$-11.46M$-13.51M
Net Income$-10.83M$-11.30M$-13.21M
EBITDA$-10.82M$-11.46M$-13.51M
Basic EPS$-0.01$-9.95$-12.36
Diluted EPS$-0.01$-9.95$-12.36

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 18Nov 15, 18 | 5:00 PM
Q2 18Aug 15, 18 | 5:00 PM
Q1 18May 12, 18 | 11:28 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
CWBRCohBar, Inc.
VECTVectivBio Holding AG
AVROAVROBIO, Inc.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
OCEAOcean Biomedical, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.